Close Menu

John Lechleiter has been named the new CEO of Eli Lilly, reports the Wall Street Journal, and Derek Lowe thinks that's unusual (but still cool) because Lechleiter's a researcher who worked his way up from the bench to management. Lowe ponders why that doesn't happen more often in pharma. One reason is that a lot of scientists don't want to be managers.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.